Payment overview · 2025
General Payments
$1,989.13
89 reported records · 22 companies
Healthcare provider profile · identity verified
Howard T Tee, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · VERO BEACH, FL · NPI 1972543486
Verified facts
What the public records show
CMS Open Payments records show Howard T Tee, MD received $1,989.13 in general payments during 2025 across 89 reported records.
Novo Nordisk Inc accounted for 10.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1405 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 304 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1405 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $210.19 | 10.6% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $207.34 | 10.4% | 11 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $202.20 | 10.2% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $196.69 | 9.9% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $170.41 | 8.6% | 6 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $105.27 | 5.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $102.26 | 5.1% | 3 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $96.19 | 4.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.11 | 4.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $90.74 | 4.6% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $84.93 | 4.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $79.81 | 4.0% | 5 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $68.60 | 3.5% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $56.18 | 2.8% | 3 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $46.17 | 2.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.38 | 2.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $39.40 | 2.0% | 2 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $28.37 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.15 | 1.1% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $17.93 | 0.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.59 | 0.8% | 1 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $14.22 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,956.86 | 88 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $207.34 | 11 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $202.20 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $177.92 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $169.72 | 8 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $112.00 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $105.27 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $102.26 | 3 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $96.19 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $92.11 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $79.81 | 5 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $68.60 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $57.70 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $56.18 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $54.20 | 3 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $46.17 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $42.38 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $42.38 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $40.93 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $36.02 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.54 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $28.37 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1405 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 201 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
201 | 52 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1405 | 349 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
201 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
304 | 82 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1405 | 349 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 1405 | 349 |
| Metoprolol Succinate | Metoprolol Succinate | 1110 | 337 |
| Atorvastatin Calcium | Atorvastatin Calcium | 964 | 295 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 898 | 288 |
| Amlodipine Besylate | Amlodipine Besylate | 885 | 276 |
| Metoprolol Tartrate | Metoprolol Tartrate | 693 | 227 |
| Losartan Potassium | Losartan Potassium | 560 | 184 |
| Sotalol | Sotalol Hcl | 543 | 156 |
| Xarelto | Rivaroxaban | 530 | 131 |
| Furosemide | Furosemide | 515 | 182 |
| Carvedilol | Carvedilol | 469 | 146 |
| Lisinopril | Lisinopril | 427 | 135 |
| Ezetimibe | Ezetimibe | 416 | 134 |
| Valsartan | Valsartan | 345 | 110 |
| Hydrochlorothiazide | Hydrochlorothiazide | 315 | 96 |
| Clopidogrel | Clopidogrel Bisulfate | 306 | 101 |
| Entresto | Sacubitril/Valsartan | 304 | 82 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 260 | 92 |
| Pravastatin Sodium | Pravastatin Sodium | 253 | 81 |
| Jardiance | Empagliflozin | 201 | 52 |
| Potassium Chloride | Potassium Chloride | 199 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 195 | 57 |
| Warfarin Sodium | Warfarin Sodium | 187 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 61 |
| Spironolactone | Spironolactone | 166 | 56 |
| Atenolol | Atenolol | 165 | 44 |
| Simvastatin | Simvastatin | 152 | 49 |
| Amiodarone Hcl | Amiodarone Hcl | 148 | 51 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 141 | 47 |
| Alprazolam | Alprazolam | 139 | 58 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 138 | 49 |
| Metformin Hcl | Metformin Hcl | 136 | 35 |
| Nebivolol Hcl | Nebivolol Hcl | 123 | 38 |
| Omeprazole | Omeprazole | 118 | 36 |
| Ramipril | Ramipril | 117 | 35 |
| Midodrine Hcl | Midodrine Hcl | 109 | 38 |
| Nitroglycerin | Nitroglycerin | 104 | 69 |
| Flecainide Acetate | Flecainide Acetate | 98 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 31 |
| Repatha Syringe | Evolocumab | 97 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 91 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 27 |
| Temazepam | Temazepam | 90 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 27 |
| Digoxin | Digoxin | 83 | 27 |
| Irbesartan | Irbesartan | 81 | 25 |
| Repatha Sureclick | Evolocumab | 77 | 18 |
| Farxiga | Dapagliflozin Propanediol | 74 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 18 |
| Ozempic | Semaglutide | 72 | 19 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 62 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 17 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Allopurinol | Allopurinol | 59 | 21 |
| Jantoven | Warfarin Sodium | 59 | 23 |
| Cephalexin | Cephalexin | 56 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 16 |
| Lorazepam | Lorazepam | 54 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 16 |
| Benazepril Hcl | Benazepril Hcl | 52 | 15 |
| Metformin Hcl Er | Metformin Hcl | 51 | 17 |
| Multaq | Dronedarone Hcl | 51 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 19 |
| Ranolazine Er | Ranolazine | 49 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 47 | 16 |
| Gabapentin | Gabapentin | 47 | 15 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | 12 |
| Verapamil Er | Verapamil Hcl | 38 | 11 |
| Vascepa | Icosapent Ethyl | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 33 | suppressed |
| Sotalol Af | Sotalol Hcl | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | 11 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Livalo | Pitavastatin Calcium | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | 11 |
| Tramadol Hcl | Tramadol Hcl | 30 | 12 |
| Candesartan Cilexetil | Candesartan Cilexetil | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 28 |
| Praluent Pen | Alirocumab | 29 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | 14 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | 11 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Edarbi | Azilsartan Medoxomil | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 11 |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 17 | suppressed |
| Verquvo | Vericiguat | 17 | suppressed |
| Eplerenone | Eplerenone | 16 | suppressed |
| Famotidine | Famotidine | 16 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 16 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 16 | suppressed |
| Dofetilide | Dofetilide | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,989.13 · 89 records | Novo Nordisk Inc | AMPLATZER AMULET, AREXVY, AVEIR, Assure WCD, Attruby, Barostim Neo System, CAMZYOS, CAPVAXIVE, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, LEQVIO, LifeVest, MITRACLIP, NEXLETOL, ONPATTRO, Optimizer, Ozempic, REPATHA, SHINGRIX, VERQUVO, VITALPATCH RTM, VYNDAQEL, WAINUA, WATCHMAN FLX, Wegovy | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error